US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus vaccine on Friday in adults aged between 50 and 59, making it the first shot endorsed for that age...